AveXis Inc., the subsidiary that manufactures Zolgensma, brought a “data manipulation issue” related to testing performed on animals to the FDA’s attention five weeks after the drug’s approval. (Photo: Shutterstock)
Novartis made headlines earlier this year with the debut of Zolgensma, the most-expensive drug to receive FDA approval to date.
Now, the drugmaker and its $2.1 million treatment are back in the headlines–this time facing potential criminal charges after the FDA said that Novartis withheld information about an error in testing data until after the drug was approved.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Emily Payne
Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.
